Introduction {#S0001}
============

With 8.7 million new cases and a specific mortality of 1.4 million cases of death in 2011, tuberculosis remains a major public health problem in the world \[[@CIT0001]\]. In 2012, African region was ranked the second region with of the highest TB cases with about 27% of worldwide cases \[[@CIT0001]\]. In the same year, the prevalence of TB cases and death in Cameroon was estimated at 69 thousands and 14.1 thousands respectively \[[@CIT0002]\]. The fight against TB remains a worldwide challenge. It was reinvigorated in 1991, when a World Health Assembly (WHA) resolution recognized TB as a major global public health problem \[[@CIT0003]\]. From that time, all actions in TB control aimed to reduce by 2015 the TB prevalence and death rates by 50% relative to 1990 \[[@CIT0004]\]. In the 18 years since the launch of a new international strategy for TB care and control by WHO in the mid-1990s (the DOTS strategy) and the subsequent global rollout of DOTS and its successor (the Stop TB Strategy) \[[@CIT0005]\], major progress has been observed. Globally, the TB mortality rate has fallen by 45% since 1990 (with about 4.66.3 million lives saved). It has also been observed that the global TB incidence rate is falling in most parts of the world \[[@CIT0006]\]. Despite these progresses, TB remains the second leading cause of death from an infectious disease worldwide \[[@CIT0001]\]. The TB specific rate deaths is unacceptably high given that most of cases are preventable if patients can access health care for a diagnosis and if they are adequately treated \[[@CIT0001]\]. According to WHO, additional efforts are needed in African Region which is currently not on track to achieve the mortality and prevalence targets \[[@CIT0001]\]. These efforts should include the identification of the determinants of death among patients undergoing anti tuberculosis treatment. Factors associated to death among TB patients are worldwide documented. They are HIV positive status, immune depression, negative pulmonary TB, malnutrition, co-morbidity with non-infectious diseases, abusive alcohol and drug used \[[@CIT0007]\]. In Cameroon, the literature describes characteristics of patients who died during tuberculosis treatment \[[@CIT0008]\]. More information is needed to improve the survival of TB patients treated on Cameroonian Anti-tuberculosis Program. In the process of identifying interventions to reduce tuberculosis burden, there is a need to identify factors associated to death among TB patients. This study had as objective to identify, amongst patients diagnosed with TB between 1996 and 2011in Baleng TB Diagnostic and Treatment Center (DTC) of West Cameroon, factors associated to TB death.

Methods {#S0002}
=======

Study design {#S20003}
------------

It was retrospective case-control study. Cases were defined as patients who died from any cause during anti tuberculosis treatment and controls were defined as patients successfully treated. Data collection was done on medical records of TB patients who came to DTC of Baleng between 1996 and 2011.

Study site {#S20004}
----------

The DTC of Baleng is the largest DTC in the western region of Cameroon with more than 20 beds exclusively for tuberculosis patients. It is located in a semi urban town belonging in Mifi Health District. In DTC of Baleng, patients are treated according to the WHO Direct Observed Treatment Strategy (DOTS) \[[@CIT0009]\]. At the end of patients' follow up, they are classified into six groups\[[@CIT0001]\]: cured (patients who are initially sputum smear-positive and who are sputum smear-negative in the last month of treatment and on at least one previous occasion); Completed treatment (patients who complete treatment but do not meet the criteria for cure or failure); Failed (patients who are initially sputum smear-positive and who remain sputum smear-positive at month 5 or later); Defaulted (patient whose treatment are interrupted for two consecutive months or more); Transferred (patients who are transferred through another DTC during anti tuberculosis treatment) and Died (patients who die from any cause during treatment). The patients who are cured or those who completed treatment are grouped into successfully treated.

Data management {#S20005}
---------------

Data was collected from April to august, 2012 by trained surveyors. They focused on patients' socio demographic characteristics, previous contact with anti tuberculosis treatment, HIV status, and clinical files of tuberculosis and treatment outcome. Epi info software version 3.5.3 was used for data entry and data analysis. In general analysis, proportions (with 95% Confident Interval: 95% CI) and means (with Standard Deviation: SD) were calculated. During case-control analysis, patients with unknown mortality status (referred and those who were lost to follow up) were excluded. Patients with incomplete data regarding exposure to suspected risk factors were also excluded. For univariate analysis Chi squared test (for qualitative variables) and Student\'s T-test (for quantitative variable) were used. To adjust the estimation of Odds Ratio (OR), multivariate logistic regression models were constructed. For the final model, significant predictors were selected using forward stepwise methods. P-values under 0.05 were considered as significant. As data were collected in patient\'s register, no informed consent was necessary. The study was approved by the administrative authorities of the Diagnostic and Treatment Center of Baleng and Mifi Health Committee.

Results {#S0006}
=======

General descriptive of participants {#S20007}
-----------------------------------

In this study, 362 cases of death and 2883 patients successfully treated were included in analysis as presented in [Figure 1](#F0001){ref-type="fig"}. The mean age at the time of diagnosis was 35.9 (SD 14.2) years old and male sex was predominant with 2020 participants (62.2% CI 60.6- 63.9). Age was further categorized into two groups: patients with age less than or equal to 40 years old and those with age above 40 years old. The number of participants aged more than 40 was 969 (29.9% CI 28.3-31.5). Among patients included in analysis, 2885 (90.9- 92.8) were new cases of TB whereas 255 (81% CI 7.2- 9.1) had an antecedent of anti-tuberculosis treatment. Clinical forms of TB were: Extra-pulmonary Tuberculosis, sputum smear-positive pulmonary TB and sputum smear-negative pulmonary TB with respective frequencies of 145 (4.5% CI 3.8- 5.3); 2677 (82.4% CI 78.4- 86.2) and 423 (13.0% CI 8.9- 17.1). Among participants with known HIV status (35.1%), 305 (26.9% CI 24.3- 29.6) were positive and among them, 77 (25.2% CI 19.9- 30.5) had been documented as taking antiretroviral therapy (ART). Death occurred for 132 (36.5%) patients before the end of the first two months of intensive phase of treatment. Globally, the ratio death/successfully treated was 0.13 and his evolution by years is presented in [Figure 2](#F0002){ref-type="fig"}.

![Participants included in the study](PAMJ-22-253-g001){#F0001}
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Factors associated to death {#S20008}
---------------------------

In univariate analysis, as presented in [Table 1](#T0001){ref-type="table"}, socio demographic-related risk factor which was significantly associated (p \< 0.05) with death was age \> 40 years. Clinical-related risk factors which were significantly associated with death were Extra-pulmonary localization of TB and Sputum smear-negative pulmonary. Male sex and antecedent of anti TB treatment were associated to patients' death but not significantly with p value of 0.31 and 0.21 respectively. Significant independent risk factors for death in multivariable logistic regression model were male sex, Sputum smear-negative pulmonary TB, extra pulmonary TB and HIV positive status. Details of multinomial logistic regression model are presented in [Table 2](#T0002){ref-type="table"}.

###### 

Comparison of death and successfully treated groups according to socio demographic and clinical characteristics

  Characteristics                      Frequencies   OR (95%CI)    p value          
  ------------------------------------ ------------- ------------- ---------------- ---------
  Male sex                             234 (11.6)    1786 (88.4)   1.1 (0.8- 1.4)   0.31
  Age \> 40 years                      115 (16.0)    814 (84.0)    1.9 (1.5- 2.3)   \< 0.01
  Extra pulmonary TB                   51 (35.2)     94 (64.8)     4.8 (3.3- 6.9)   \< 0.01
  Sputum smear-negative pulmonary TB   86 (20.3)     337 (79.7)    2.7 (2.1- 3.6)   \< 0.01
  Antecedent of anti TB treatment      32 (12.5)     223 (87.5)    1.2 (0.8- 1.7)   0.21
  HIV positive                         78 (25,6)     227 (74,4)    4,5 (3,1- 6,6)   \< 0,01
  Anti-Retroviral Treatment            17 (22,1)     60 (77,9)     0,7 (0,4- 1,3)   0,14

###### 

Multinomial logistic regression of factors associated to death of TB patients treated in DTC of Baleng, 1996- 2011

  Characteristics                      Adjusted OR   95% Confidence Interval   p value
  ------------------------------------ ------------- ------------------------- ---------
  Male sex                             1.5           1.0- 2.3                  0.04
  Age \> 40 years                      1.3           0.9- 2.1                  0.13
  Sputum smear-negative pulmonary TB   2.7           1.7- 4.4                  \<0.01
  Extra pulmonary tuberculosis         3.0           1.6- 5.4                  \<0.01
  HIV positive                         4.8           3.2- 7.4                  \<0.01

Discussion {#S0009}
==========

This study which aimed to identify factors associated to TB patients' death has shown that, male sex, sputum smear-negative pulmonary TB, Extra-pulmonary TB and HIV positive status were significant independent risk factors for death among TB patients treated in DTC of Baleng between 1996 and 2011. During the study, data were extracted from TB patients' records which can be a source of potential information biases. Despite it, the power of the study was good due to the number of participants (2883) and to the number of deaths (362). The strongest factor associated to death among study population was the positive HIV status. This association has been observed in others studies implemented in different settings \[[@CIT0007], [@CIT0010]--[@CIT0012]\]. The synergy action of M. tuberculosis and HIV is well known and documented. These two pathogens potentiate one another, accelerating the deterioration of immunological functions and resulting in premature death if untreated or inadequately treated \[[@CIT0013]\]. Taking into account the high burden of these diseases and their effects on mortality of co-infected patients, the World Health Organization recommend implementation of collaborative TB/HIV activities. One of these activities is the provision of antiretroviral therapy (ART) to all TB patients with HIV infection \[[@CIT0004]\]. The effect of ART on the survival of TB patients is well documented \[[@CIT0014]--[@CIT0016]\]. Despite this benefit of ART, the implementation of collaborative TB/HIV activities on the field remains difficult due to several management challenges that compromise programmatic implementation in resource-limited settings \[[@CIT0017]\]. In our study for example, only 25.2% (77) of patients with HIV positive status were on ART. Despite it, ART was protective factor of death in univariate analysis. The second factor identified as associated to TB patients' death in our study was Extra-pulmonary localization of TB. In fact, patients with Extra-pulmonary localization of TB had three times more risk to die compared to those with pulmonary TB. Extra-pulmonary TB as factor associated to death has been documented in Barcelona, Spain after a population-based cohort study \[[@CIT0012]\]. On the other hand, analysis of European surveillance data has shown that Extra-pulmonary TB is protective of death compared to pulmonary TB. Explanation which can be given to this is the rarity of severe forms of Extra-pulmonary TB in the European population. Another explanation can be the fact that during that European study, patients with both pulmonary and Extra-pulmonary TB were included under pulmonary TB \[[@CIT0018]\]. Nevertheless, at our knowledge, evaluation of association between Extra-pulmonary TB and patients' death is not yet explored in sub-Saharan African Countries. Further study should therefore focus on the exploration of that association. The third strongest factor associated to death was sputum smear-negative disease. That association has been shown by other studies elsewhere \[[@CIT0007], [@CIT0010]\]. This association can be explain by the fact that, in setting with high prevalence of HIV, sputum smear-negative is the expression of advance immune depression \[[@CIT0007], [@CIT0019]\]. And thus, the deaths in these cases are due to opportunistic diseases related to AIDS. In our study, the male sex was also associated to patients' death. The same results have been shown by others studies \[[@CIT0011], [@CIT0018], [@CIT0020]\]. However, tuberculosis among women remains a major public health issue because it is among the top three killers of women worldwide \[[@CIT0001]\]. WHO estimate that, in most low-income countries, twice as many men are notified with tuberculosis as women due to socioeconomic and cultural factors leading to barriers in assessing health by women \[[@CIT0021]\]. Intervention aimed to reduce mortality among TB patients should thus target both men and women.

Conclusion {#S0010}
==========

The aim of this study was to identify factors associated to death among tuberculosis patients treated under Cameroonian National Anti-tuberculosis Program. After the reviewed of TB patients' records treated from 1996 to 2011 in a major DTC of Bafoussam, West Cameroon, factors associated to patients' death was HIV positive status, Extra-pulmonary TB, sputum smear-negative pulmonary TB and male sex. These groups at risk have to be closely follow-up during anti-tuberculosis treatment to achieve the sixth Millennium Development Goals. Moreover, studies are needed to identify and test efficient interventions of mortality reduction among TB patients in limited settings.

We sincerely thank TCHASSE Floriane, personnel of Center for Diagnostic and Treatment of tuberculosis of Lafe-Baleng for his precious contributions in collecting data and "Better Access to Health Care" association which sponsors this research.

Competing interests {#S0011}
===================

The authors declare no competing of interest.

Authors' contributions {#S0012}
======================

FDN: conception and design the study, acquisition, analysis and interpretation of data, drafting the manuscript. MN and PSFK: acquisition of data and final approval of the version published. HD, AVN and STMA: final approval of the version published. All authors have read and agreed to the final version of this manuscript and have equally contributed to its content and to the management of the case.
